TY - JOUR
T1 - Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface
AU - Vermunt, Lisa
AU - Otte, Marco
AU - Verberk, Inge M. W.
AU - Killestein, Joep
AU - Lemstra, Afina W.
AU - van der Flier, Wiesje M.
AU - Pijnenburg, Yolande A. L.
AU - Vijverberg, Everard G. B.
AU - Bouwman, Femke H.
AU - Gravesteijn, Gido
AU - van de Berg, Wilma D. J.
AU - Scheltens, Philip
AU - van Harten, Argonde C.
AU - Willemse, Eline A. J.
AU - Teunissen, Charlotte E.
N1 - Funding Information:
This project received funding from the Selfridges Group Foundation administered by the Weston Brain Institute and ZonMw Verspreiding en implementatie impuls (VIMP #7330502061).
Funding Information:
M. Otte, I. M.W. Verberk, Afina W. Lemstra, Yolande A.L. Pijnenburg, F.H. Bouwman, A.C. van Harten, E.A. J. Willemse, G. Gravesteijn report no disclosures relevant to the manuscript. L. Vermunt is advisory consultant for Roche (fees paid to Amsterdam UMC). J. Killestein has accepted speaker and consulting fees from Merck, Biogen, TEVA, Sanofi, Genzyme, Roche, and Novartis. E.G.B. Vijverberg is advisory consultant for several pharmaceutical companies in the field of neurodegeneration. W.M. van der Flier has (had) a collaboration contract, performed contract research, received grants, was invited speaker, or was consultant for Biogen MA, Boehringer Ingelheim, Life‐MI, AVID, Roche BV, Fujifilm, Combinostics, Eisai, Danone, ADx Neurosciences, Oxford Health Policy Forum CIC, Roche, and WebMD Neurology (fees paid to Amsterdam UMC). P. Scheltens is employed by LSP and Amsterdam UMC. P. Scheltens has received consultancy fees (paid to Amsterdam UMC) from AC Immune, Brainstorm Cell, EIP, ImmunoBrain Checkpoint, Genentech, Novartis, Novo Nordisk. He is PI of studies with AC Immune, FUJI‐film/Toyama, UCB, and Vivoryon (fees paid to Amsterdam UMC). C.E. Teunissen CT has a collaboration contract with ADx Neurosciences, performed contract research or received grants from Probiodrug, AC Immune, Biogen‐Esai, CogRx, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio, and Roche (fees paid to Amsterdam UMC).
Publisher Copyright:
© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
PY - 2022/11
Y1 - 2022/11
N2 - Interpretation of axonal damage biomarker Neurofilament Light chain (NfL) concentrations is difficult due to the lack of age-specific and disease-specific reference values. We here developed an interactive interface to support interpretation of NfL results in human body fluids. We used NfL values of 1698 individuals without a neurological disorder, aged 19–85 years, and patients with MS and dementias. Percentile regression estimates per diagnosis populate interactive graphs, alongside NfL background information (available on: https://mybiomarkers.shinyapps.io/Neurofilament). This accessible interface provides reference for interpretation of the individual patient results for clinicians. It showcases an adaptable method to support interpretation of age-dependent biomarkers in neurology.
AB - Interpretation of axonal damage biomarker Neurofilament Light chain (NfL) concentrations is difficult due to the lack of age-specific and disease-specific reference values. We here developed an interactive interface to support interpretation of NfL results in human body fluids. We used NfL values of 1698 individuals without a neurological disorder, aged 19–85 years, and patients with MS and dementias. Percentile regression estimates per diagnosis populate interactive graphs, alongside NfL background information (available on: https://mybiomarkers.shinyapps.io/Neurofilament). This accessible interface provides reference for interpretation of the individual patient results for clinicians. It showcases an adaptable method to support interpretation of age-dependent biomarkers in neurology.
UR - https://www.scopus.com/pages/publications/85139424685
U2 - 10.1002/acn3.51676
DO - 10.1002/acn3.51676
M3 - Article
C2 - 36196979
SN - 2328-9503
VL - 9
SP - 1832
EP - 1837
JO - Annals of clinical and translational neurology
JF - Annals of clinical and translational neurology
IS - 11
ER -
SDG 3 Good Health and Well-being